Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study

Sharon B Wigal, Earl Nordbrock, Akwete L Adjei, Ann Childress, Robert J Kupper, Laurence Greenhill, Sharon B Wigal, Earl Nordbrock, Akwete L Adjei, Ann Childress, Robert J Kupper, Laurence Greenhill

Abstract

Background: Psychostimulants remain first-line treatment options for the management of attention-deficit/hyperactivity disorder (ADHD). A multilayer extended-release bead methylphenidate capsule (provisional name Aptensio XR™, MPH-MLR) with unique release properties is being investigated for the treatment of ADHD.

Objective: The aim of this study was to assess the efficacy (primary) and safety and tolerability (secondary) of MPH-MLR compared with placebo in children and adolescents aged 6-18 years with ADHD.

Methods: This study was a parallel, double-blind, multicenter, placebo-controlled, forced-dose, phase III study in which patients were randomized to placebo or MPH-MLR 10, 15, 20, or 40 mg given once daily. There were four study phases: (1) 4-week screening/baseline; (2) 1-week, double-blind treatment (DBP); (3) 11-week, open-label, dose-optimization period; and (4) 30-day follow-up call. During the open-label dose-optimization period all patients started with MPH-MLR 10 mg, unless the investigator deemed it necessary to begin at a higher dose, and were titrated to an optimized dose (10, 15, 20, 30, 40, 50, 60 mg; all given once daily) based on response and adverse events (AEs). The primary endpoint was the change from baseline to end of DBP in ADHD Rating Scale, 4th Edition (ADHD-RS-IV) total score. Secondary endpoints included changes in ADHD-RS-IV subscales and Clinical Global Impression-Improvement Scale (CGI-I) at the end of the DBP. The primary analysis was an analysis of covariance including terms for treatment, site, and baseline ADHD-RS-IV total score.

Results: A total of 221 patients completed the DBP. The primary endpoint had a statistically significant difference among treatments (p = 0.0046) and sites (p = 0.0018), and baseline covariate made a significant contribution (p < 0.0001). As the MPH-MLR dose increased, the ADHD-RS-IV total score improved; the 20 and 40 mg doses were statistically different (p = 0.0145 and p = 0.0011, respectively) from placebo. Females responded differently than did males (p = 0.0238); there was a significant difference among treatments for males but not for females, partly because only one-third of subjects were female and partly because some females who received placebo had considerable improvement during the DBP. Similarly, the ADHD-RS-IV subscales and CGI-I scores at the end of the DBP also showed more improvement as the dose of MPH-MLR increased. During the open-label phase, ADHD-RS-IV total scores improved (mean change from baseline -22.5) and correlated as the dose of MPH-MLR increased; CGI-I scores also improved. No unexpected AEs were noted.

Conclusions: Dose-related improvements in ADHD-RS-IV scores that exceeded those of placebo were observed in patients treated with MPH-MLR. No new safety signals were noted.

Trial registration: ClinicalTrials.gov NCT01239030.

Figures

Fig. 1
Fig. 1
Patient disposition
Fig. 2
Fig. 2
Mean decrease in ADHD-RS-IV total score (a); hyperactivity subscale score (b); and inattention subscale score (c) from baseline (day 0) to the end of the double-blind phase (day 7; efficacy population; n = 221). ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, MPH-MLR methylphenidate multilayer extended-release capsules. *p = 0.0145 vs. placebo; **p = 0.0011 vs. placebo; †p = 0.0840 vs. placebo; ††p = 0.0061 vs. placebo; ‡p = 0.0118 vs. placebo; ‡‡p = 0.0026 vs. placebo
Fig. 3
Fig. 3
Mean CGI-I scores at end of the double-blind phase (day 7: efficacy population; n = 221). CGI-I Clinical Global Impression-Improvement Scale, MPH-MLR methylphenidate multilayer extended-release capsules, SD standard deviation. *p = 0.0311 vs. placebo; **p = 0.0072 vs. placebo
Fig. 4
Fig. 4
Arithmetic mean ADHD-RS-IV total scores (lower numbers indicate improvement) from 1 week following the beginning of open-label dose optimization (visit 4) to the end of the open-label phase (visit 8) (efficacy population; n = 221). ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition
Fig. 5
Fig. 5
Arithmetic mean CGI-I scores from 1 week following the beginning of open-label dose optimization (visit 4) to the end of the open-label phase (visit 8) (efficacy population; n = 221). CGI-I Clinical Global Impression-Improvement Scale
Fig. 6
Fig. 6
Mean ADHD-RS-IV total score and mean MPH-MLR dose from 1 week following the beginning of open-label dose optimization (visit 4) to the end of the open-label phase (visit 8) (patients completing open-label phase, n = 200). ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, MPH-MLR methylphenidate multilayer extended-release capsules

References

    1. Centers for Disease Control and Prevention. Attention deficit hyperactivity disorder (ADHD). . Accessed 17 June 2014.
    1. Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–1022. doi: 10.1542/peds.2011-2654.
    1. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy. 2003;23(10):1281–1299. doi: 10.1592/phco.23.12.1281.32697.
    1. Quillivant XR™ (methylphenidate hydrochloride) product information. New York: NextWave Pharmaceuticals (2013). . Accessed 24 July 2013.
    1. Wigal SB, Wigal TL, Kollins SH. Advances in methylphenidate drug delivery systems for ADHD therapy. Adv ADHD. 2006;1:4–7.
    1. Ermer JC, Adeyi BA, Pucci ML. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. CNS Drugs. 2010;24(12):1009–1025. doi: 10.2165/11539410-000000000-00000.
    1. National Institute of Mental Health. Attention deficit hyperactivity disorder (ADHD) (2012). . Accessed 17 June 2014.
    1. Adjei A, Teuscher NS, Kupper RJ, Chang W-W, Greenhill L, Newcorn J, et al. Single-dose pharmacokinetics of methylphenidate extended-release administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin®) in healthy adult volunteers. J Child Adolesc Psychopharmacol. 2014;24(10):570–578. doi: 10.1089/cap.2013.0135.
    1. Adjei A, Kupper RJ, Teuscher NS, Wigal S, Sallee FR, Childress A, et al. Steady-state bioavailability of methylphenidate extended-release (MPH-MLR) capsule versus methylphenidate immediate-release tablets (Ritalin®) in healthy adult volunteers. Clin Drug Invest. 2014;34(11):795–805. doi: 10.1007/s40261-014-0234-x.
    1. Wigal SB, Greenhill LL, Nordbrock E, Connor DF, Kollins SH, Adjei A, et al. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24(10):562–569. doi: 10.1089/cap.2014.0100.
    1. Rhodes Pharmaceuticals, L.P. Efficacy and safety of methylphenidate HCl ER capsules in children and adolescents with ADHD [ identifier NCT01239030]. US National Institutes of Health, . . Accessed 22 March 2015.
    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR) Washington, DC: American Psychiatric Association; 2000.
    1. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980–988. doi: 10.1097/00004583-199707000-00021.
    1. Axelrod BN. Validity of the Wechsler abbreviated scale of intelligence and other very short forms of estimating intellectual functioning. Assessment. 2002;9(1):17–23. doi: 10.1177/1073191102009001003.
    1. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. doi: 10.1176/appi.ajp.2011.10111704.
    1. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: checklist, norms, and clinical interpretation. New York: Guilford Press; 1998.
    1. Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007;4(7):28–37.
    1. Findling RL, Bukstein OG, Melmed RD, Lopez FA, Sallee FR, Arnold LE, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(1):149–159. doi: 10.4088/JCP.v69n0120.
    1. Robb AS, Findling RL, Childress AC, Berry SA, Belden HW, Wigal SB. Efficacy, safety, and tolerability of a novel methylphenidate extended-release oral suspension (MEROS) in ADHD. J Atten Disord. 2014
    1. Teuscher NS, Adjei A, Findling RL, Greenhill L, Kupper RJ, Wigal SB. Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple layer beads (MPH-MLR) in pediatric subjects with attention-deficit/hyperactivity disorder. Drug Des Devel Ther (in press).
    1. Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord. 2006;10(1):92–111. doi: 10.1177/1087054705286049.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel